Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics, Inc. (JSPR)
:JSPR
JSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.65 - $30.70
Previous CloseN/A
Volume4.28M
Average Volume (3M)260.49K
Market Cap
$57.23M
Enterprise Value$251.06M
Total Cash (Recent Filing)$129.40M
Total Debt (Recent Filing)$3.44M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
May 09, 2025EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.87
Shares Outstanding15,022,122
10 Day Avg. Volume202,840
30 Day Avg. Volume260,485
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.43
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap4.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-63.53
Forecast
1Y Price Target
$60.38Price Target Upside1484.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Jasper Therapeutics News
See All JSPR News
---
Bulls Say, Bears Say
Bulls Say
Clinical DataThe updated results are trending positively, with the new sub-analysis supporting dose responsive efficacy for briquilimab, and safety continuing to look promising.
Market OpportunityBEACON now includes omalizumab-naive patients, which could grow the addressable population for JSPR.
Safety ProfileThe briquilimab study continues to demonstrate a best-in-class tolerability profile, giving JSPR the potential to differentiate.
Bears Say
Competitive PositionThe current stock price is baking in apprehension around the balance sheet in the context of being behind CLDX from a timeline perspective.
Financial ConcernsWith a cash balance of just over $70 million at the end of 2024, Jasper will clearly need to raise additional capital or secure a partnership to advance briquilimab development.
Long-term SafetyMore follow-up will be needed to fully understand the risk of tox accumulation over time.
---
Ownership Overview
27.62% Insiders
9.56% Mutual Funds
0.02% Other Institutional Investors
54.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JSPR FAQ
What was Jasper Therapeutics, Inc.’s price range in the past 12 months?
Jasper Therapeutics, Inc. lowest stock price was $3.65 and its highest was $30.70 in the past 12 months.
What is Jasper Therapeutics, Inc.’s market cap?
Jasper Therapeutics, Inc.’s market cap is $57.23M.
When is Jasper Therapeutics, Inc.’s upcoming earnings report date?
Jasper Therapeutics, Inc.’s upcoming earnings report date is May 09, 2025 which is in 33 days.
How were Jasper Therapeutics, Inc.’s earnings last quarter?
Jasper Therapeutics, Inc. released its earnings results on Feb 27, 2025. The company reported -$1.62 earnings per share for the quarter, missing the consensus estimate of -$1.254 by -$0.366.
Is Jasper Therapeutics, Inc. overvalued?
According to Wall Street analysts Jasper Therapeutics, Inc.’s price is currently Undervalued.
Does Jasper Therapeutics, Inc. pay dividends?
Jasper Therapeutics, Inc. does not currently pay dividends.
What is Jasper Therapeutics, Inc.’s EPS estimate?
Jasper Therapeutics, Inc.’s EPS estimate is -1.35.
How many shares outstanding does Jasper Therapeutics, Inc. have?
Jasper Therapeutics, Inc. has 15,022,122 shares outstanding.
What happened to Jasper Therapeutics, Inc.’s price movement after its last earnings report?
Jasper Therapeutics, Inc. reported an EPS of -$1.62 in its last earnings report, missing expectations of -$1.254. Following the earnings report the stock price went down -2.241%.
Which hedge fund is a major shareholder of Jasper Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JSPR
---
Jasper Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.38 (1484.78% Upside)
$60.38 (1484.78% Upside)
Blogger Sentiment
Bullish
JSPR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 239.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.16%
12-Months-Change
Fundamentals
Return on Equity
-101.73%
Trailing 12-Months
Asset Growth
-16.23%
Trailing 12-Months
Company Description
Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
---
JSPR Stock 12 Month Forecast
Average Price Target
$60.38
▲(1484.78% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering JSPR
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-39.24%
reiterated a buy rating last month
Copying Jay Olson's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -39.24% per trade.
---